item management s discussion and analysis of financial condition and results of operations note regarding forward looking statements this annual report on form k contains historical information as well as forward looking statements 
statements looking forward in time are included in this annual report pursuant to the safe harbor provisions of the private securities litigation reform act of such statements involve known and unknown risks and uncertainties that may cause the company s actual results in future periods to be materially different from any future performance suggested herein 
overview during fiscal  bio reference expanded its laboratory testing capabilities and its customer base through internal growth 
previously  the company completed a series of acquisitions  as discussed below  to enhance its position in the health information marketplace 
the company licensed software from a third party to allow for the grouping for analysis of medical claims data and has proceeded to develop its own proprietary algorithms and enhancements to the licensed software so as to include laboratory and prescription data 
this project  called psimedica population strategies in medicine  is currently working with two erisa funds which total over  lives as beta sites for its analytical tools and programs 
the company expects to seek customers for its psimedica products during fiscal year the company acquired certain assets of doctorny 
com www 
doctorny 
com  a health portal which  with its associated domain sites and existing physician websites  includes website development capabilities for health care providers  together with a search engine which allows consumers to locate physicians by region  credentials  specialty or other parameters 
the company announced the consumer view represented by doctorny 
com was part of its entry into the e health marketplace 
the company developed a business to business internet strategy which was assigned to its new careevolve 
com business unit 
this unit is currently developing physician services to enhance physician patient and physician payor electronic communications on a secure basis ie  preserving confidentiality  including communicating laboratory results  e mail prescriptions  refills  payor verification and eligibility 
the careevolve system will further offer physicians claims processing  cme credits  immunization records and promote e commerce services  including physician supplies  office supplies and computer hardware 
the company acquired certain assets of right body foods  inc rbf  a manufacturer and distributor of freshly prepared  starch free  low calorie  low carbohydrate  food products  located in syosset  new york 
its products are sold through health professionals  dieticians  nutritionists and physicians 
see item herein 
results of operations net income comparing only the laboratory operations of the company and excluding the one time write down of an impaired asset and its associated increase in reserve of accounts receivable which occurred in fiscal year  the company s laboratory operations showed net income for the year of  compared to a loss of  in the prior year 
this turn around is related by and large to an increase in net revenues which is reflective of an increase in the number of tests per patient and in the frequency of more expensive or specialty testing services 
rbf had a loss of  for the year ended october  careevolve had a loss of  for the year ended october  including careevolve and rbf  the company realized net income of  for fiscal as compared to a loss  including the write down of the impaired asset  of  for the prior year 
net revenues net revenues for the year ended october  were  as compared to  for the year ended october   this represents a increase in net revenues 
this increase is due to a increase in patients serviced and a increase in net revenues per patient and is reflective of an increase in number of tests per patient serviced and in the frequency of more expensive or specialty testing services 
the company s laboratory operations had net revenues of  in fiscal  of which mli had net revenues of  careevolve had net revenues of  and rbf had net revenues of  the number of patients serviced during the year ended october  was  which was greater when compared to the prior fiscal year s twelve month period 
net revenue per patient for the year ended october  was compared to net revenue per patient for the year ended october  of  an increase of or 
mli s net revenue per patient was for the year ended october  as compared to for the year ended october   a decrease of or 
in august  the company announced that its genpath business unit resumed full service oncology testing to physicians and institutions 
while genpath had been offering limited oncology testing services since it was formed after the sale of the gencare laboratory to impath in  genpath currently offers full service hematology oncology and some genomic testing to its customers 
the company s non competition agreement with impath expired in april  bio reference is assembling a scientific staff and a marketing sales force in order to duplicate the success that gencare had in this market 
cost of sales cost of sales  excluding careevolve and rbf  increased from  for the year ended october  to  for the year ended october  this represents a increase in direct operating costs 
this increase is related to the increase in net revenues of 
careevolve and rbf had cost of sales of  during this period 
gross profits gross profits on net revenues  excluding careevolve and rbf  increased to  for the year ended october  from  for the year ended october   an increase of   primarily attributable to the increase in net revenues 
gross profit margins increased to from  primarily attributable to the increase in net revenues per patient and the operating efficiencies realized with regard to the increase in net revenues 
management believes that the company s automated chemistry laboratory will have enough capacity to handle the projected increase in patient volume 
the company s total gross profit was  careevolve and rbf had a gross loss of  for the year ended october  general and administrative expenses general and administrative expenses for the year ending october  were  as compared to  for the year ended october   an increase of  or 
during the year ended october   the company wrote down an impaired asset of  attributable to its end stage renal dialysis business acquired from smith kline beecham and the associated increase in reserves on its accounts receivable of  without the write down and increase in reserves  the increase in indirect expenses would have been  or as compared with fiscal this increase was caused primarily by three factors  an increase in marketing related expense of  an increase in bad debt of  and an increase in data processing expense of  all of which are attributable to the company s growth 
careevolve and rbf had general and administrative expenses of approximately  for the year ended october  interest expense interest expense increased from  during the year ended october  to  during the year ending october  an increase of  management believes that this trend will continue in the future due to the expected increased use of the company s revolving line of credit to fund the company s expansion and growth 
income comparing only the laboratory operations of the company and excluding the one time write down of an impaired asset and its associated increase in reserve of accounts receivable which occurred in fiscal year  the company s laboratory showed net income for fiscal of  compared to a loss of  for fiscal this turn around is related by and large to an increase in net revenues which is reflective of an increase in the number of tests per patient and in the frequency of more expensive or specialty testing services 
rbf had a loss of  for the year ended october  careevolve had a loss of  during the year ended october  including careevolve and rbf  the company realized net income of  in fiscal compared to a loss  including the write down of the impaired asset  of  in fiscal fiscal year compared to fiscal year net income the company s net income loss for the years ended october  and was  and  respectively 
the main reasons for the  decrease in net income is the write down of approximately  for impaired assets including the additional allowance for accounts receivable relating to the company s end stage renal dialysis business acquired from smithkline beecham of approximately  and an increase in general and administrative expenses of approximately  in fiscal 
in addition  net revenue per patient decreased during the twelve month period ended october   as compared to the twelve month period ended october  gross profit margins decreased from for the twelve month period ended october  to for the twelve month period ended october  based upon anticipated increases in patient volume  anticipated increased testing to be performed  reimbursement rate improvements  and anticipated decreases in operating costs  the bulk of the effects of which were expected to be realized in the second half of fiscal  the company projected net income for fiscal net revenues net revenues for the year ended october  were  as compared to  for the year ended october   this represents a increase in net revenues 
mli had net revenues of  or of the company s net revenues for fiscal the company acquired mli in april of  for the seven month period ended october   mli had net revenues of  or of the company s net revenue for the twelve month period ended october  the number of patients serviced during the fiscal year ended october  was  which was greater when compared to the prior fiscal year 
mli accounted for of the patient count for the year ended october  net revenue per patient for the year ended october  was compared to net revenue per patient for the year ended october  of  a reduction of or 
this decrease is due to the inclusion of a full twelve months of mli s revenues with its associated lower revenue per patient in fiscal year mli s net revenue per patient was for the twelve month period ended october  compared to net revenue per patient of in fiscal year the company expected an increase in net revenues in fiscal year due to a number of factors internal growth  an estimated increase in the contract with the new york state department of corrections  medicare reimbursement for tests previously not covered  an increase in medicare reimbursement for other selected tests  as well as new marketing initiatives in newer testing areas  such as drugs of abuse testing  and complimentary and alternative medicine 
in addition  the company identified three new business initiatives see below  all of which it sought to leverage off existing capabilities the company possesses 
the company anticipated increasing its revenues in fiscal through internal growth and development of new marketing initiatives in laboratory testing services outside the traditional physician market 
in november  the contract to provide laboratory testing by the new york state department of corrections for inmates in its facilities was renewed 
this contract was valued at approximately  for fiscal year  an estimated increase of approximately from fiscal year the company is seeking to market its services to other correctional institutions 
in december  the company announced the acquisition of doctorny 
com www 
doctorny 
com  a health portal which  with its associated domain sites and existing physician websites  includes website development capabilities for health care providers  together with a search engine which allows consumers to locate physicians by region  credentials  specialty or other parameters 
the company announced the consumer view represented by doctorny 
com was part of its entry into the e health marketplace 
the company plans to further develop the physician services offered by the system to enhance physician patient and physician payor electronic communications on a secure basis ie  preserving confidentiality  including communicating laboratory results  e mail prescriptions  refills  payor verification and eligibility  etc 
the offering of physician cme credits through the system is also contemplated 
the company intends to market these services to its existing physician network as well as to other individual physicians and groups of physicians 
in december  the company acquired right body foods  inc  a manufacturer and distributor of freshly prepared  starch free  low calorie  low carbohydrate  food products  located in syosset  new york 
its products are sold through health professionals  dieticians  nutritionists and physicians 
the company expected to use its marketing staff and physician network to increase the distribution of these products 
see item herein 
cost of services cost of sales increased from  for the year ended october  to  for the year ended october   an increase of  or 
this increase was primarily the result of the mli acquisition 
mli s direct operating costs were  for the twelve month period ended october   as compared to  for the seven month period ended october   an increase of  the optimum consolidation of laboratory operations had not been completed and was expected to only marginally impact the company s cost structure until the automated laboratory upgrade and expansion was completed 
while the automated laboratory was expected to have a marginal impact on cost structure  the reduction of the company s dependence on reference laboratories was expected to have a more favorable impact during the second half of fiscal gross profits gross profit on net revenues increased from  for the year ended october  to  for the year ended october   an increase of  primarily attributable to the increase in revenues 
gross profit margins decreased from for the year ended october  to for the year ended october  management believed that the company s gross profit margin would increase in fiscal  due to increased revenues from internal growth  medicare reimbursement for tests not previously covered  increases in reimbursement rates from medicare on certain tests  the completion of the automated chemistry laboratory and decrease in direct operating expenses 
the decrease in gross profit margins in fiscal was primarily attributable to the lower net revenues per patient  the increase in direct costs associated with mli and the duplication of direct costs that had not been eliminated as of october  by an optimum consolidation of laboratory operations 
the company invested a large amount of time and money during fiscal to increase its processing capacity 
management believes that its capacity  once the automated chemistry laboratory is completed for approximately  will be more than adequate to handle the projected increase in patient volume 
general and administrative expenses general and administrative expenses for the year ended october  were  as compared to  for the year ended october   an increase of approximately  or 
approximately of this increase was the impairment charge of approximately  associated with the company s end stage renal dialysis business acquired from smithkline beecham 
in addition  occupancy expenses  telephone  data processing and marketing expenses increased approximately  over the prior twelve month period 
the company recorded a  expense associated with a new jersey medicaid overpayment claim 
management believed that general and administrative expenses in would increase but not at a higher percentage than the projected increase in revenues 
interest expense interest expense increased from  for the year ended october  to  for the year ended october   resulting from the company s continuing use of its revolving line of credit with pnc bank 
note regarding forward looking statements this annual report on form k contains historical information as well as forward looking statements 
statements looking forward in time are included in this annual report pursuant to the safe harbor provisions of the private securities litigation reform act of such statements involve known and unknown risks and uncertainties that may cause the company s actual results in future periods to be materially different from any future performance suggested herein 
liquidity and capital resources for the fiscal year ended october  the company s working capital at october  was approximately  as compared to approximately  at october   a decrease of  the company decreased its cash position by approximately  during the current period 
the company utilized approximately  in cash for operating activities 
to offset this use of cash  the company borrowed  in short term debt and repaid approximately  in existing debt 
the company had current liabilities of approximately  at october  the company entered into an agreement during fiscal with one of its vendors to convert approximately  of accounts payable obligations into a three year term debt 
management believes operating costs will be lower during fiscal year due to cost savings generated by the automated laboratory 
credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base 
the company does have significant receivable balances with government payors and various insurance carriers 
generally  the company does not require collateral or other security to support customer receivables  however  the company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable 
the company establishes and maintains an allowance for uncollectible accounts based upon collection history and anticipated collection  and as a consequence  believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements 
in january  the company commenced negotiations with new jersey medicaid regarding a claim the claim made by the state in december that with respect to certain clinical laboratory tests for which reimbursements were made by the state to the company  although such tests were authorized by the physician  the underlying laboratory test requisitions did not bear the actual signature of the physician ordering the test 
the company believes it had been compliant with all requirements regarding claims submitted for payment by new jersey medicaid and in fact requires actual physician signatures before it bills new jersey medicaid 
however  in order to dispose of this issue  the company and new jersey medicaid entered into an oral agreement in january to settle the claim for approximately  and the company accrued this settlement amount in its october  financial statements 
the settlement was approved by the director of the new jersey division of medical assistance 
the company paid the settlement amount during fiscal and on june   a warrant to discharge the certificate of debt against the company was filed in the superior court of new jersey 
in april  the company amended its revolving loan agreement with pnc bank 
the maximum amount of the credit line available to the company is the lesser of  or ii of the company s qualified accounts receivable 
as defined in the agreement 
plus of any face amount of the certificates of deposit  if any  pledged as collateral for this loan minus the amount of any portion of the outstanding principal balance of the term loan which is deemed to be collateralized by the certificates of deposit 
interest on advances are currently at prime plus and are scheduled to increase to prime plus at april  the credit line is collateralized by substantially all of the company s assets and the assignment of a  insurance policy on the life of the president of the company 
the line of credit is available through september and may be extended for annual periods by mutual consent thereafter 
the terms of this agreement contain  among other provisions  requirements for maintaining defined levels of capital expenditures and net worth  various financial ratios and insurance coverage 
as of october   the company was in compliance with the covenant provisions of this agreement and was utilizing  of this credit facility 
as of october   the company was in default of its tangible net worth and one other covenant 
the company received waivers for these defaults in january as of october   the company was utilizing  of this credit facility 
note regarding forward looking statements this annual report on form k contains historical information as well as forward looking statements 
statements looking forward in time are included in this annual report pursuant to the safe harbor provisions of the private securities litigation reform act of such statements involve known and unknown risks and uncertainties that may cause the company s actual results in future periods to be materially different from any future performance suggested herein 
the company intends to expand its laboratory operations through aggressive marketing while also diversifying into related medical fields through acquisitions 
these acquisitions may involve cash  notes  common stock  and or combinations thereof 
the company has various employment and consulting agreements of up to seven years with commitments totaling approximately  
see note of the notes to the consolidated financial statements herein 
and operating leases with commitments totaling approximately  of which approximately  and  are due during fiscal 
see notes and 
the company s cash balances at october  totaled approximately  as compared to  at october  the company believes that its cash position  the anticipated cash generated from future operations  the availability of its credit line with pnc bank  the utilization of certificates of deposits maturing during the first quarter of fiscal year and the interest due thereupon  will meet its future cash needs 
impact of inflation to date  inflation has not had a material effect on the company s operations 
new authoritative pronouncements the financial accounting standards board fasb issued statement of financial accounting standards sfas no 
 accounting for derivative instruments and hedging activities deferral of effective date of fasb statements no 
the statement defers for one year the effective date of fasb statement no 
 accounting for derivative instruments and hedging activities 
the rule now will apply to all fiscal quarters of all fiscal years beginning after june  the statement will require the company to recognize all derivatives on the balance sheet at fair value 
derivatives that are not hedges must be adjusted to fair value through income 
if the derivative is a hedge  depending on the value of the hedged assets  liabilities  or firm commitments are recognized through earnings or are recognized in other comprehensive income until the hedged item is recognized in earnings 
the ineffective portion of a derivative s change in fair value will be immediately recognized in earnings 
the adoption of sfas no 
is not expected to have a material impact on the company s consolidated results of operation  financial position or cash flows 
item a 
quantitative and qualitative disclosure about market risk not applicable 

